Results 1 to 10 of about 1,089 (172)

Arylpiperazine Derivatives and Cancer: A New Challenge in Medicinal Chemistry [PDF]

open access: yesPharmaceuticals
Background: In recent decades, there has been a startling rise in the number of cancer patients worldwide, which has led to an amazing upsurge in the development of novel anticancer treatment candidates.
Giorgia Andreozzi   +8 more
doaj   +9 more sources

Design and Synthesis of Arylpiperazine Serotonergic/Dopaminergic Ligands with Neuroprotective Properties [PDF]

open access: yesMolecules, 2022
Long-chain arylpiperazine scaffold is a versatile template to design central nervous system (CNS) drugs that target serotonin and dopamine receptors. Here we describe the synthesis and biological evaluation of ten new arylpiperazine derivatives designed ...
Margherita Mastromarino   +8 more
doaj   +6 more sources

Investigation of antibacterial activity of cinnamyl derivatives of arylpiperazine [PDF]

open access: yesArchives of Biological Sciences, 2012
The derivatives of cinnamic acid and N-arylpiperazine show antibacterial activity. In this work the potential synergistic effect of cinnamyl derivatives of arylpiperazine in selected bacteria was investigated.
Novaković Irena   +5 more
doaj   +6 more sources

Synthesis, bioactivity, and molecular docking of novel arylpiperazine derivatives as potential AR antagonists [PDF]

open access: yesFrontiers in Chemistry, 2022
Prostate cancer is one of the malignant tumors and the second most common malignant tumor in men. Clinically used androgen receptor (AR)–targeted drugs can antagonize androgen and inhibit tumor growth, but these drugs can cause serious resistance ...
Yueheng Qi   +5 more
doaj   +2 more sources

Design, Synthesis and Pharmacological Evaluation of Novel Conformationally Restricted N-arylpiperazine Derivatives Characterized as D2/D3 Receptor Ligands, Candidates for the Treatment of Neurodegenerative Diseases [PDF]

open access: yesBiomolecules, 2022
Most neurodegenerative diseases are multifactorial, and the discovery of several molecular mechanisms related to their pathogenesis is constantly advancing.
Thayssa Tavares da Silva Cunha   +7 more
doaj   +2 more sources

Structural Aspects of Arylpiperazines as Aminergic GPCR Ligands. [PDF]

open access: yesMolecules
Arylpiperazines are considered a “privileged scaffold” in medical chemistry due to their versatility and modular structure, enabling modifications towards diverse molecular targets with desired potency, selectivity, and pharmacokinetic properties.
Bartyzel A, Cristóvão B, Kaczor AA.
europepmc   +4 more sources

Modulating Properties of Piroxicam, Meloxicam and Oxicam Analogues against Macrophage-Associated Chemokines in Colorectal Cancer [PDF]

open access: yesMolecules, 2021
The mechanisms underlying the antineoplastic effects of oxicams have not been fully elucidated. We aimed to assess the effect of classic and novel oxicams on the expression/secretion of macrophage-associated chemokines (RTqPCR/Luminex xMAP) in colorectal
Paulina Lewandowska   +8 more
doaj   +2 more sources

New Oxicam Derivatives—Studies of Membrane Interactions, Cytotoxicity, Cyclooxygenase Inhibition and Molecular Docking [PDF]

open access: yesMembranes
Oxicam derivatives, a class of nonsteroidal anti-inflammatory drugs (NSAIDs), are important scaffolds for developing biologically active compounds. In this study, arylpiperazine oxicam derivatives (PR24–PR50) were examined for membrane interactions ...
Jadwiga Maniewska   +4 more
doaj   +2 more sources

The Structural Determinants for α1-Adrenergic/Serotonin Receptors Activity among Phenylpiperazine-Hydantoin Derivatives [PDF]

open access: yesMolecules, 2021
Several studies confirmed the reciprocal interactions between adrenergic and serotoninergic systems and the influence of these phenomena on the pathogenesis of anxiety.
Katarzyna Kucwaj-Brysz   +8 more
doaj   +2 more sources

Arylpiperazine Derivative NAF19 Inhibits Prostate Cancer Activity and Its Molecular Mechanisms [PDF]

open access: yesDrugs in R&D
Background and Objectives Androgen deprivation therapy (ADT) remains the primary treatment for advanced prostate cancer. However, most patients relapse within 18–24 months, progressing to castration-resistant prostate cancer (CRPC) which is currently ...
Hua Jiang   +3 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy